[zosia bluszcz]

aktualnie rekrutujace pacjentki (Avastin, Herceptyna i Xeloda)


Zainspirowana watkiem na "Nowotwory damy rade" grzebnelam w necie i znalazlam ponizsze.
Poniewaz badania kliniczne prowadzone w PL sa na ogol chowane pod korcem maku wiec skopiowalam tutaj liste dot. polskich osrodkow.
Mozna ja odnalezc w tym linku
http://www.roche-trials.c.../catg10080.html
(panstwa sa wymienone w kolejnosci alfabetycznej).
Tamze klikniecie na tytul badania daje wglad w bardziej szczegolowe warunki rekrutacji.


Mam nadzieje, ze sie ta lista komus przyda.

Klucz do podstawowych warunkow:

*HER2-Positive Early Breast Cancer=dodatni HER2, wczesny rak piersi

*HER2 Positive Metastatic Breast Cancer=dodatni HER2, rak piersi z przerzutami

*HER2-Negative Metastatic Breast Cancer =ujemny HER2, rak piersi z przerzutami

*Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer =terapia podtrzymujaca, pacjentki z ujemnym HER2 i przerzutami

*Adjuvant Therapy in Triple Negative Breast Cancer= terapia adjuwantowa, rak potrojnie negatywny

*Metastatic Breast Cancer = rak piersi z przerzutami



Poland

Bialystok
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting

Bydgoszcz
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting

Elblag
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting

Gdansk
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Recruiting

Gdansk
A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Recruiting

Gliwice
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting

Gliwice
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Recruiting

Krakow
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting

Krakow
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting

Lodz
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting

Lodz
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Recruiting

Lublin
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting

Lublin
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting

Olsztyn
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting

Poznan
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting

Poznan
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting

Poznan
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting

Rybnik
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting

Szczecin
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting

Ul. 28 Czerwca 1956 Nr 194
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting

Ul. 28 Czerwca 1956 Nr 194
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting

Warszawa
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting

Warszawa
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting

Warszawa
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting

Wroclaw
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting